Diagnostics

SomaSignalTM tests bring life-changing health information to the point of care

See the tests

One blood sample, 7,000 protein measures. Multiple answers to clinical questions across dozens of disease states, including cardiovascular, kidney, neurological, cancer, and more.

SomaSignal tests give patients, providers, and payers around the world more accurate, dynamic, and trusted health information by revealing clinically significant insights specific to the patient across many areas of health.

Become a test provider

How do SomaSignal tests work for clinical use?

hexagon icon with number 1 inside

Step 1

Order a SomaSignal test from a licensed physician

hexagon icon with #2 inside

Step 2

Visit a lab and have a blood sample drawn

hexagon icon with #3 inside

Step 3

Physician receives test results within two to three weeks and schedules a follow-up consultation

SomaSignal tests are changing how people receive care.

Hexagon icon showing 7K representing 7000 proteins tested in SomaSignal tests

7,000+ protein measurements

Hexagon icon showing over 1 Billion measurements for SomaSignal tests

>1B protein measurements to date and growing

Hexagon icon showing large 10-log dynamic range for SomaSignal tests

10-log dynamic range

Hexagon icon showing 300 publications and patents available for SomaSignal tests

>300 supporting, peer-reviewed publications and >700 patents

Hexagon icon showing 450K SomaSignal tests

450K+ samples

Hexagon icon showing the number 16 for 16 validated tests

16 clinically validated SomaSignal tests

Early signals. Early interventions.

SomaSignal tests act as the early warning system for disease.

Utilizing comprehensive protein detection technology, SomaSignal tests
provide a snapshot of a person’s health status and detect early signs
that a patient may be headed for a severe health event.

Icon of lab sample representing meaningful tests

Get clinically meaningful tests

With just a single blood test, SomaSignal tests deliver medical insights across 21 clinically validated areas, turning those insights into actionable medical information.

Icon of cross symbolizing optmization of care

Optimize care

SomaSignal tests help providers make better and more personalized treatment decisions by guiding patients toward actions that can improve their health and help them avoid a severe health event.

Icon showing line chart trending up symbolizing adjusted treatment

Adjust treatment based on insights

Test results reveal whether existing treatments are adequately reducing risk or if patients may benefit from underutilized therapies that may deliver better outcomes – potentially changing the course of disease.

Icon of line chart trending up symbolizing risk of health event

Identify patients at risk of a severe health event

SomaSignal tests scan for markers across dozens of disease areas, allowing the accurate identification of patients who are at highest risk of a health event, resulting in better care and lower costs.

Cardiovascular disease is the leading cause of death and disability among people with type 2 diabetes1

More than 800,000 people in the U.S. die from cardiovascular disease each year — that’s 1 in every 3 deaths – and about 160,000 of them occur in people under age 65.1

Only 8%
31%
65%
Only 8%

of type 2 diabetic patients are taking guideline recommended cardioprotective medicines, regardless of their cardiovascular disease risk.2

31%

of T2D patients are at high risk of CVD3

65%

of people with diabetes will die from some sort of heart disease or stroke – that’s 2x more likely as someone who doesn’t have the condition.4

1. Centers for Disease Control and Prevention, Million Hearts® initiative https://millionhearts.hhs.gov/learn-prevent/cost-consequences.html#:~:text=Approximately%201.5%20million%20heart%20attacks,in%20people%20under%20age%2065
2. Optum-United Health Group. Commercial and Medicare Advantage analysis of cardioprotective medication use in type 2 diabetic patients. Unpublished data analysis. August 2022.
3. SomaLogic. Meta-cohort analysis of patients with type 2 diabetes. Data on file. August 2022.
4. American Heart Association and the Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/diabetes/library/features/diabetes-and-heart.html

Act early. Identify type 2 diabetic patients more likely to have a major acute cardiovascular event with the CardioDM test.

Patients identified as high risk with the CardioDM test have been shown to have a 43.4% likelihood of a cardiovascular event or death within a 4-year time horizon, with a median time-to-event of about 20 months.5
Learn about the CardioDM test

5. Williams SA, et al. A proteomic surrogate for cardiovascular outcomes that is sensitive to multiple mechanisms of change in risk. Sci Transl Med. 2022 Apr 6;14(639):eabj9625. https://www.science.org/doi/10.1126/scitranslmed.abj9625

SomaSignal tests in the news

The GuardianNew blood test predicts risk of heart attack and stroke with twice previous accuracy

Read article

SomaLogic on YouTubeProteomics and Development of Blood Tests for Cardiac Disease

Watch video

The Healthcare Technology ReportThe Top 25 Biotech CEOs of 2022

Read article

Deep evidence-based science. Pioneering technology.

Over the last few decades, SomaLogic has undertaken hundreds of research projects and real-world clinical studies – all to advance the study of how proteins work in multi-dimensional patterns to predict a person’s health status and potential health risks.

icon of hexagons symbolizing innovation in care

Innovation in care delivery

For more than 20 years, SomaLogic has been on a mission to help people live healthier and longer lives. Through a passionate commitment to revolutionize care, we’re bringing actionable medical information to every patient, provider, and payer.

Icon of clipboard

Evidence-based

With more than 800 patents and hundreds of peer-reviewed publications, evidence forms the backbone of the SomaScan® Assay, which fuels our SomaSignal™ tests.

Icon of stethescope attached to phone

Advanced use of technology

We leverage sophisticated machine learning and bioinformatics capabilities to transform a massive collection of big data into quantitative risk assessments and reliable insights across many dimensions of human disease.

Icon of proteins

Extensive proteome coverage

The SomaScan® Platform provides more coverage of the human proteome than any other technology. Today, we are on a path to discover the 20,000 or so known proteins in the human proteome, giving us a comprehensive, evidence-based testing platform.

Start transforming patient care

Order a test

SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic Operating Co., Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory